{"success":true,"data":{"pressRelease":{"id":"66511","rtpr_id":"nPn2kd7Kka","ticker":"GNPX","exchange":"NASDAQ","all_tickers":["GNPX"],"title":"Genprex to Participate at BIO International Convention 2026","author":"PR Newswire","published_at":"2026-06-17T13:00:19.596Z","article_body":"Genprex to Participate at BIO International Convention 2026\n\nPR Newswire\n\nAUSTIN, Texas, June 17, 2026\n\nThe BIO International Convention Brings Together More Than 20,000 Biotech\nIndustry Leaders From Around The World\n\nAUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=2005819443&u=https%3A%2F%2Fwww.genprex.com%2F&a=Genprex%2C+Inc.)\n(\"Genprex\" or the \"Company\") (NASDAQ: GNPX), a clinical-stage gene therapy\ncompany focused on developing life-changing therapies for patients with cancer\nand diabetes, today announced that its team will be attending and\nparticipating at the BIO 2026 International Convention taking place June\n22-25, 2026 in San Diego, California.\n\nIn attendance from Genprex's executive leadership team will be Thomas\nGallagher, Senior Vice President of Intellectual Property and Licensing.\nThroughout the duration of the conference, Mr. Gallagher will be available\nin-person to conduct one-on-one meetings with industry groups to provide an\noverview of the Company's gene therapies for cancer and diabetes.\n\nFor those interested in meeting with Mr. Gallagher or other members of\nGenprex's management team, please request a meeting through the conference\nmeeting portal or by contacting Investor Relations at investors@genprex.com\n(mailto:investors@genprex.com) .\n\nThe BIO International Convention is the largest and most comprehensive event\nfor biotechnology, representing the full ecosystem of biotech with 20,000\nindustry leaders from across the globe.\n\nAbout Genprex, Inc.\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing\nlife-changing therapies for patients with cancer and diabetes. Genprex's\ntechnologies are designed to administer disease-fighting genes to provide new\ntherapies for large patient populations with cancer and diabetes who currently\nhave limited treatment options. Genprex works with world-class institutions\nand collaborators to develop drug candidates to further its pipeline of gene\ntherapies in order to provide novel treatment approaches. Genprex's oncology\nprogram utilizes its systemic, non-viral Oncoprex® Delivery System which\nencapsulates the gene-expressing plasmids using lipid-based nanoparticles in a\nlipoplex form. The resultant product is administered intravenously, where it\nis taken up by tumor cells that then express tumor suppressor proteins that\nwere deficient in the tumor. The Company's lead product candidate, Reqorsa®\nGene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical\ntrials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer\nclinical programs has received a Fast Track Designation from the FDA for the\ntreatment of that patient population, and Genprex's SCLC program has received\nan FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is\ncomprised of a novel infusion process that uses an AAV vector to deliver Pdx1\nand MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002\ntransforms alpha cells in the pancreas into functional beta-like cells, which\ncan produce insulin but may be distinct enough from beta cells to evade the\nbody's immune system. In a similar approach for Type 2 diabetes, where\nautoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish\nexhausted beta cells.\n\nInterested investors and shareholders are encouraged to sign up for press\nreleases and industry updates by visiting the Company Website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=3109320354&u=https%3A%2F%2Fwww.genprex.com%2F&a=Company+Website)\n, registering for Email Alerts\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=2942824840&u=https%3A%2F%2Fwww.genprex.com%2Femail-alerts%2F&a=Email+Alerts)\n and by following Genprex on Twitter\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=2488908356&u=https%3A%2F%2Ftwitter.com%2Fgenprex&a=Twitter)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=4109979343&u=https%3A%2F%2Ffacebook.com%2Fgenprexinc&a=Facebook)\nand LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=3044771909&u=http%3A%2F%2Flinkedin.com%2Fcompany%2Fgenprex&a=LinkedIn)\n.\n\nCautionary Language Concerning Forward-Looking Statements\nStatements contained in this press release regarding matters that are not\nhistorical facts are \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995. These forward-looking\nstatements are made on the basis of the current beliefs, expectations and\nassumptions of management, are not guarantees of performance and are subject\nto significant risks and uncertainty. These forward-looking statements should,\ntherefore, be considered in light of various important factors, including\nthose set forth in Genprex's reports that it files from time to time with the\nSecurities and Exchange Commission and which you should review, including\nthose statements under \"Item 1A – Risk Factors\" in Genprex's Annual Report\non Form 10-K for the year ended December 31, 2025.\n\nBecause forward-looking statements are subject to risks and uncertainties,\nactual results may differ materially from those expressed or implied by such\nforward-looking statements. Such statements include, but are not limited to,\nstatements regarding: Genprex's ability to advance the clinical development,\nmanufacturing and commercialization of its product candidates in accordance\nwith projected timelines and specifications; the timing and success of\nGenprex's clinical trials, its intended regulatory submissions and any\nresulting regulatory approvals; the effect of Genprex's product candidates,\nalone and in combination with other therapies, on cancer and diabetes;\nGenprex's future growth and financial status, including Genprex's ability to\nmaintain compliance with the continued listing requirements of The Nasdaq\nCapital Market and to continue as a going concern and to obtain capital to\nmeet its long-term liquidity needs on acceptable terms, or at all; Genprex's\ncommercial and strategic partnerships, including those with its third party\nvendors, suppliers and manufacturers and their ability to successfully perform\nand scale up the manufacture of its product candidates; Genprex's intellectual\nproperty and licenses; and Genprex's current expectations, estimates,\nforecasts and projections about the industry and markets in which it operates.\n\nThese forward-looking statements should not be relied upon as predictions of\nfuture events and Genprex cannot assure you that the events or circumstances\ndiscussed or reflected in these statements will be achieved or will occur. If\nsuch forward-looking statements prove to be inaccurate, the inaccuracy may be\nmaterial. You should not regard these statements as a representation or\nwarranty by Genprex or any other person that Genprex will achieve its\nobjectives and plans in any specified timeframe, or at all. You are cautioned\nnot to place undue reliance on these forward-looking statements, which speak\nonly as of the date of this press release. Genprex disclaims any obligation to\npublicly update or release any revisions to these forward-looking statements,\nwhether as a result of new information, future events or otherwise, after the\ndate of this press release or to reflect the occurrence of unanticipated\nevents, except as required by law.\n\nGenprex, Inc.\n(877) 774-GNPX (4679)\n\nGNPX Investor Relations\ninvestors@genprex.com (mailto:investors@genprex.com)\n\nGNPX Media Contact\nKalyn Dabbs\nmedia@genprex.com (mailto:media@genprex.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-international-convention-2026-302802751.html\n(https://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-international-convention-2026-302802751.html)\n\nSOURCE Genprex, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS607668/Genprex_2_Logo.jpg?id=OA2721417\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn2kd7Kka","title":"Genprex to Participate at BIO International Convention 2026","author":"PR Newswire","ticker":"GNPX","created":"2026-06-17T13:00:19.596Z","tickers":["GNPX"],"exchange":"NASDAQ","article_body":"Genprex to Participate at BIO International Convention 2026\n\nPR Newswire\n\nAUSTIN, Texas, June 17, 2026\n\nThe BIO International Convention Brings Together More Than 20,000 Biotech\nIndustry Leaders From Around The World\n\nAUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=2005819443&u=https%3A%2F%2Fwww.genprex.com%2F&a=Genprex%2C+Inc.)\n(\"Genprex\" or the \"Company\") (NASDAQ: GNPX), a clinical-stage gene therapy\ncompany focused on developing life-changing therapies for patients with cancer\nand diabetes, today announced that its team will be attending and\nparticipating at the BIO 2026 International Convention taking place June\n22-25, 2026 in San Diego, California.\n\nIn attendance from Genprex's executive leadership team will be Thomas\nGallagher, Senior Vice President of Intellectual Property and Licensing.\nThroughout the duration of the conference, Mr. Gallagher will be available\nin-person to conduct one-on-one meetings with industry groups to provide an\noverview of the Company's gene therapies for cancer and diabetes.\n\nFor those interested in meeting with Mr. Gallagher or other members of\nGenprex's management team, please request a meeting through the conference\nmeeting portal or by contacting Investor Relations at investors@genprex.com\n(mailto:investors@genprex.com) .\n\nThe BIO International Convention is the largest and most comprehensive event\nfor biotechnology, representing the full ecosystem of biotech with 20,000\nindustry leaders from across the globe.\n\nAbout Genprex, Inc.\nGenprex, Inc. is a clinical-stage gene therapy company focused on developing\nlife-changing therapies for patients with cancer and diabetes. Genprex's\ntechnologies are designed to administer disease-fighting genes to provide new\ntherapies for large patient populations with cancer and diabetes who currently\nhave limited treatment options. Genprex works with world-class institutions\nand collaborators to develop drug candidates to further its pipeline of gene\ntherapies in order to provide novel treatment approaches. Genprex's oncology\nprogram utilizes its systemic, non-viral Oncoprex® Delivery System which\nencapsulates the gene-expressing plasmids using lipid-based nanoparticles in a\nlipoplex form. The resultant product is administered intravenously, where it\nis taken up by tumor cells that then express tumor suppressor proteins that\nwere deficient in the tumor. The Company's lead product candidate, Reqorsa®\nGene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical\ntrials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer\nclinical programs has received a Fast Track Designation from the FDA for the\ntreatment of that patient population, and Genprex's SCLC program has received\nan FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is\ncomprised of a novel infusion process that uses an AAV vector to deliver Pdx1\nand MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002\ntransforms alpha cells in the pancreas into functional beta-like cells, which\ncan produce insulin but may be distinct enough from beta cells to evade the\nbody's immune system. In a similar approach for Type 2 diabetes, where\nautoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish\nexhausted beta cells.\n\nInterested investors and shareholders are encouraged to sign up for press\nreleases and industry updates by visiting the Company Website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=3109320354&u=https%3A%2F%2Fwww.genprex.com%2F&a=Company+Website)\n, registering for Email Alerts\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=2942824840&u=https%3A%2F%2Fwww.genprex.com%2Femail-alerts%2F&a=Email+Alerts)\n and by following Genprex on Twitter\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=2488908356&u=https%3A%2F%2Ftwitter.com%2Fgenprex&a=Twitter)\n, Facebook\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=4109979343&u=https%3A%2F%2Ffacebook.com%2Fgenprexinc&a=Facebook)\nand LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4713385-1&h=3044771909&u=http%3A%2F%2Flinkedin.com%2Fcompany%2Fgenprex&a=LinkedIn)\n.\n\nCautionary Language Concerning Forward-Looking Statements\nStatements contained in this press release regarding matters that are not\nhistorical facts are \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995. These forward-looking\nstatements are made on the basis of the current beliefs, expectations and\nassumptions of management, are not guarantees of performance and are subject\nto significant risks and uncertainty. These forward-looking statements should,\ntherefore, be considered in light of various important factors, including\nthose set forth in Genprex's reports that it files from time to time with the\nSecurities and Exchange Commission and which you should review, including\nthose statements under \"Item 1A – Risk Factors\" in Genprex's Annual Report\non Form 10-K for the year ended December 31, 2025.\n\nBecause forward-looking statements are subject to risks and uncertainties,\nactual results may differ materially from those expressed or implied by such\nforward-looking statements. Such statements include, but are not limited to,\nstatements regarding: Genprex's ability to advance the clinical development,\nmanufacturing and commercialization of its product candidates in accordance\nwith projected timelines and specifications; the timing and success of\nGenprex's clinical trials, its intended regulatory submissions and any\nresulting regulatory approvals; the effect of Genprex's product candidates,\nalone and in combination with other therapies, on cancer and diabetes;\nGenprex's future growth and financial status, including Genprex's ability to\nmaintain compliance with the continued listing requirements of The Nasdaq\nCapital Market and to continue as a going concern and to obtain capital to\nmeet its long-term liquidity needs on acceptable terms, or at all; Genprex's\ncommercial and strategic partnerships, including those with its third party\nvendors, suppliers and manufacturers and their ability to successfully perform\nand scale up the manufacture of its product candidates; Genprex's intellectual\nproperty and licenses; and Genprex's current expectations, estimates,\nforecasts and projections about the industry and markets in which it operates.\n\nThese forward-looking statements should not be relied upon as predictions of\nfuture events and Genprex cannot assure you that the events or circumstances\ndiscussed or reflected in these statements will be achieved or will occur. If\nsuch forward-looking statements prove to be inaccurate, the inaccuracy may be\nmaterial. You should not regard these statements as a representation or\nwarranty by Genprex or any other person that Genprex will achieve its\nobjectives and plans in any specified timeframe, or at all. You are cautioned\nnot to place undue reliance on these forward-looking statements, which speak\nonly as of the date of this press release. Genprex disclaims any obligation to\npublicly update or release any revisions to these forward-looking statements,\nwhether as a result of new information, future events or otherwise, after the\ndate of this press release or to reflect the occurrence of unanticipated\nevents, except as required by law.\n\nGenprex, Inc.\n(877) 774-GNPX (4679)\n\nGNPX Investor Relations\ninvestors@genprex.com (mailto:investors@genprex.com)\n\nGNPX Media Contact\nKalyn Dabbs\nmedia@genprex.com (mailto:media@genprex.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-international-convention-2026-302802751.html\n(https://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-international-convention-2026-302802751.html)\n\nSOURCE Genprex, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS607668/Genprex_2_Logo.jpg?id=OA2721417\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-17T13:00:19.645403717Z","server_sent_at_ms":1781701219645},"received_at":"2026-06-17T13:00:19.786Z","source_url":"https://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-international-convention-2026-302802751.html"},"analysis":{"id":"55927","press_release_id":"66511","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Genprex announced that its executive team will attend the BIO 2026 International Convention in San Diego from June 22-25.\n\nThomas Gallagher, Senior Vice President of Intellectual Property and Licensing, will be available for one-on-one meetings to discuss the company's gene therapies for cancer and diabetes.\n\nGenprex is a clinical-stage company developing therapies utilizing its Oncoprex Delivery System and lead candidate Reqorsa for lung cancer.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference attendance -- no material news."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Thomas Gallagher","role":"Senior Vice President of Intellectual Property and Licensing"},{"name":"Kalyn Dabbs","role":"Media Contact"}],"products":["Oncoprex Delivery System","Reqorsa Gene Therapy","quaratusugene ozeplasmid","GPX-002"],"companies":[{"name":"Genprex, Inc.","ticker":"GNPX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement regarding participation in an industry conference with no clinical data, regulatory updates, or financial guidance provided."},"tickerRelevance":{"others":[],"primary":"GNPX"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference_attendance","sectorWeight":"biotech"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Genprex announced that its executive team will attend the BIO 2026 International Convention in San Diego from June 22-25.\n\nThomas Gallagher, Senior Vice President of Intellectual Property and Licensing, will be available for one-on-one meetings to discuss the company's gene therapies for cancer and diabetes.\n\nGenprex is a clinical-stage company developing therapies utilizing its Oncoprex Delivery System and lead candidate Reqorsa for lung cancer.","key_figures":null,"named_entities":{"people":[{"name":"Thomas Gallagher","role":"Senior Vice President of Intellectual Property and Licensing"},{"name":"Kalyn Dabbs","role":"Media Contact"}],"products":["Oncoprex Delivery System","Reqorsa Gene Therapy","quaratusugene ozeplasmid","GPX-002"],"companies":[{"name":"Genprex, Inc.","ticker":"GNPX"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-17T13:45:05.914Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference_attendance","sectorWeight":"biotech"}},"durationMs":95099,"modelName":"george-droid-qwen-72b"}}